Phoenix Children’s Research Institute at the University of Arizona College of Medicine – Phoenix has been awarded three new R01 grants from the National Institutes of Health (NIH), the gold standard of federally funded research awards.Grant funding will advance pediatric lung and spine research.Continue reading
Author Archive: AZBio
Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy to Newborn Screenings
WASHINGTON—DECEMBER 16, 2025 — The U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. today approved the addition of Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) to the Recommended Uniform Screening Panel (RUSP) following scientific review and public comment. Early detection of both conditions allows children to receive FDA-approved therapies at the most effective time, helping to slow disease progression and preserve their quality of life.
NuvOx Announces First Patient in Phase IIb Stroke Trial
Tucson, AZ –December 15, 2025, NuvOx Therapeutics, Inc. (“NuvOx”) announced that the first patient has been enrolled in the Phase IIb NOVEL trial (NanO2 in Large Vessel Occlusion Stroke (NOVEL): a multicenter single-blind, randomized, placebo-controlled biomarker end point clinical trial of perfluorocarbon in acute ischemic stroke due to large vessel occlusion (LVO).
The NOVEL trial is funded by the Efficacy and Mechanism Evaluation (EME) Program, a partnership between the National Institute for Health Care Research (NIHR) and the Medical Research Council (MRC). The trial is also co-sponsored by the University of Glasgow and NHS Greater Glasgow and Clyde.Continue reading
U of A College of Medicine – Phoenix and Onvida Health announce groundbreaking rural health partnership
The University of Arizona College of Medicine – Phoenix and Onvida Health are partnering to launch Arizona’s first rural regional medical school branch. Deeply rooted in community, the partnership will address the severe physician shortage facing the rural regions of the state.Continue reading
Smarter tools for peering into the microscopic world
Breakthroughs in microbial analysis could enhance disease prediction, environmental protection and our understanding of the planet’s smallest life formsContinue reading
AZBio Celebrates Trailblazers 2025
AZBio and members of the Arizona Business and Bioscience Community came together honor Arizona Legislators and State and Local Elected Officials who have made it possible for the Arizona Bioscience Industry to gain national recognition, build capital infrastructure, and take its place as a leader in both scientific discovery and job growth.Continue reading
Biennial Report on Best Practices in Bioscience Economic Development Initiatives Released
WASHINGTON, DC (December 2, 2025) – The Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released today its latest biennial report on best practices in bioscience economic development initiatives: The U.S. Bioscience Industry: A Powerful Engine for State Economies.Continue reading
Governor Katie Hobbs Appoints Debbie Johnston to Lead Arizona Department of Health Services
News Release November 24, 2025 – Phoenix, AZ – Today, Governor Katie Hobbs announced the appointment of Debbie Johnston to lead the Arizona Department of Health Services. For the past 21 years, she has worked for the Arizona Hospital and Healthcare Association (AzHHA), focusing on policy development and regulatory affairs. During her tenure at AzHHA, Debbie served on various public health boards and committees at the Arizona Department of Health Services, including the State Trauma Advisory Board and the Arizona Health Improvement Plan Steering Committee. Debbie retired earlier this year as Executive Vice President for the Association.Continue reading
Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
- Acquisition adds a new growth vertical to Abbott’s already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments
- Acquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier lives
- Exact Sciences’ product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testing
- Acquisition will be immediately accretive to Abbott’s revenue growth and gross margin
- Abbott to host investor call today at 8 a.m. Central Time/9 a.m. Eastern Time
Hexoskin Medical System Receives FDA 510(k) Clearance for Long-Term ECG and Respiratory Monitoring
Montreal, Canada — November 19, 2025 — Carré Technologies Inc. (dba Hexoskin), a pioneer in wearable health technologies, today announced that its Hexoskin Medical System (HMS) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for continuous long-term ECG, respiratory monitoring, and activity. The system, which includes a smart biometric shirt and a secure data management platform, has now been cleared for use in the United States to record, display, and store electrocardiogram (ECG) and respiratory signals in ambulatory patients.
The Hexoskin Medical System enables real-world cardiopulmonary monitoring—a critical unmet need in healthcare and clinical research. With FDA clearance, HMS becomes one of the first medical-grade wearable systems capable of long-term ECG and respiratory measurements outside the clinic, transforming how patients are monitored and how treatments are evaluated.Continue reading